To analyze the efficacy of α-interferon in the treatment of acute respiratory virus infection and its effects on T helper cell 1 (Th1)/T helper cell 2 (Th2) and lung function.

A total of 79 patients with acute respiratory virus infection admitted to North Hospital of Ankang Central Hospital from December 2020 to December 2022 were divided into observation group 35 cases and control group 44 cases using random number table method. Both groups were given routine symptomatic treatment, the control group received nebulized inhalation of ribavirin injection, and the observation group received recombinant human interferon α-2b injection nebulized inhalation. Compare the clinical efficacy and time of symptom disappearance after treatment between the two groups; The pulmonary function indexes [forced vital capacity (FVC), forced expiratory volume in the first second (FEV₁), peak expiratory flow (PEF)] before and after treatment were detected, the proportion of Th1 and Th2 cells was detected, and the Th1/Th2 value was calculated. Serum C-reactive protein (CRP), interleukin (IL-6), and tumor necrosis factor were detected-α (TNF-α) Horizontal.

The total effective rate of the observation group was 31 cases(88.57%), significantly higher than that of the control group 30 cases(68.18%)(P<0.05); After treatment, the disappearance time of throat pain, cough, runny nose, and fever in the observation group was (80.43±11.35)h, (65.28±15.63)h, (35.52±11.24)h, and (34.32±8.64)h, respectively, which were significantly shorter than those in the control group [92.64±15.49)h, (80.47±11.28)h, (57.26±13.44)h, and (51.37±10.12)h, respectively, P<0.05]; After treatment, the FVC, FEV₁, and PEF in the observation group were (1.35±0.24)L, (2.47±0.42)L, and (195.32±30.12)L/min, respectively, which were significantly higher than those in the control group [1.22±0.18)L, (2.06±0.39)L, and (177.58±28.42)L/min, respectively, P<0.05]; After treatment, the Th1 and Th1/Th2 values in the observation group were (11.24±2.08)% and (1.77±0.53)%, respectively, significantly higher than those in the control group (9.36±1.55)% and (1.35±0.42)%, respectively). The Th2 values in the observation group were (6.33±0.87)%, lower than those in the control group (6.92±1.13)%(P<0.05); Post treatment observation group CRP, IL-6, TNF- α The levels were (8.63±1.95) mg/L, (34.26±6.51) pg/ml, and (118.62±9.17) pg/ml, respectively, which were significantly lower than those in the control group [(14.25±3.76) mg/L, (51.22±9.06) pg/ml, (146.02±11.64) pg/ml, P<0.05].

α- Interferon has a good therapeutic effect on acute respiratory virus infection, which is beneficial for promoting Th1/Th2 cell balance and reducing CRP, IL-6, and TNF- α Level, can promote the recovery of lung function in patients, with high safety.